[Inhibition of incretin degradation--a new therapy principle for treatment of type 2 diabetes?].
Gallwitz
B
B
Medizinische Klinik I, St.-Josef-Hospital, Ruhr-Universität Bochum.
Schmidt
W E
WE
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000201:enzymology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology; D018819:Dipeptidyl Peptidase 4 / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007532:Isoleucine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010446:Peptide Fragments / Q000378:metabolism*; D051381:Rats; D011924:Rats, Zucker; D013844:Thiazoles / Q000008:administration & dosage*
D001786:Blood Glucose; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D013844:Thiazoles; C114061:isoleucyl-thiazolidide; D007532:Isoleucine; C055453:glucagon-like peptide 1 (7-36)amide; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D018819:Dipeptidyl Peptidase 4